This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Atara Biotherapeutics, Inc.
Drug Names(s): AMG 745
PINTA 745 is a novel myostatin inhibiting peptibody. A peptibody is a protein construct made of a synthetic peptide that is fused to an antibody.
In preclinical studies, PINTA 745 was able to reduce inflammation and build muscle in models of chronic kidney disease.
PINTA 745 was previously called AMG 745, which was originally being developed by Amgen.
Amgen and Atara
In October 2012, Amgen and Kleiner Perkins Caufield & Byers (KPCB) announced the formation of Atara Biotherapeutics, a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including nephrology and oncology. Financial terms of the transaction are not being disclosed. Atara will have licenses to six Amgen assets, which are in various stages of development, ranging from preclinical to Phase I.
PINTA 745 News
Additional information available to subscribers only: